

13th November, 2025

To,
**THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: INFINIUM**

Dear Sir/Madam,

Sub: Submission of Unaudited Financial Results for the Half Year ended 30th September 2025, (Standalone and Consolidated) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we hereby submit the Unaudited Financial Results of the Company (Standalone and Consolidated) with Limited Review for the half year ended 30th September 2025, duly approved by the Board of Directors at its meeting held on 13th November, 2025.

The following documents are enclosed herewith:

- Outcome of Board Meeting as per Regulation 30 and other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- Statement of Unaudited Financial Results (Standalone) for the half year ended 30th September 2025 with Limited Review Report issued by the Auditors of the Company.
- Statement of Unaudited Financial Results (Consolidated) for the half year ended 30th September 2025 with Limited Review Report issued by the Auditors of the Company.

We request you to kindly take the same on record.

Thanking You,
Yours Sincerely,
FOR, INFINIUM PHARMACHEM LIMITED

**SANJAYKUMAR VITHTHALBHAI PATEL
MANAGING DIRECTOR
DIN: 00370715**

13th November, 2025

To,
**THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: INFINIUM**

Dear Sir/Madam,

Sub: Outcome of Board Meeting

This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. With reference to the captioned subject and in furtherance to our intimation letter dated November 05, 2025, we hereby inform the stock exchange that the Board of Directors of the company at its meeting held today i.e. **Thursday, November 13, 2025** inter-alia decided as under:

1. Considered and approved Standalone unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2025.
2. Considered and approved Consolidated unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2025.
3. The Board took note of the Statement of Deviation and variation in utilization of funds raised through IPO and Preferential issue for the half year ended September 30 2025. Pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015, the Board noted that the company has maintained transparency and there is no deviation in utilization of the funds raised.

Kindly note that the meeting of the Board of Directors of the Company commenced at **12:00 p.m.** and concluded at **02:00 p.m.**

We request you to kindly take the same on record.

Thanking You,
Yours Sincerely,
FOR, INFINIUM PHARMACHEM LIMITED

**SANJAYKUMAR VITHTHALBHAI PATEL
MANAGING DIRECTOR
DIN: 00370715**

ASHOK RAJPARA & CO

Chartered Accountants

Independent Auditor's Review Report on Standalone Unaudited Half Yearly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **INFINIUM PHARMACHEM LIMITED** ('the Company') for the half year ended September 30, 2025 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of interim Financial Information Performed by the Independent Auditor of the Entity's, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, ASHOK RAJPARA & CO
CHARTERED ACCOUNTANTS



(ASHOK RAJPARA)
PROPRIETOR

M. No. 100559

FRN No : 153195W

UDIN : 25100559BMNYFA8255

Place : SURAT

Date : 13/11/2025

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

STATEMENT OF STANDALONE FINANCIAL RESULT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2025

PARTICULARS	Half- year ended			(Rs. In Lacs)
	30.09.2025	31.03.2025	30.09.2024	Year ended
	Unaudited	Audited	Unaudited	31.03.2025
INCOME				
Revenue from Operations	7260.37	6562.06	7129.58	13691.64
Other Income, net	38.33	101.15	111.79	212.94
TOTAL INCOME	7298.70	6663.21	7241.37	13904.58
EXPENSES				
Cost of Material Consumed	5675.42	4996.03	5790.57	10786.6
Purchases of Traded Goods	0	0	0	0.00
Changes In Inventories of FG., WIP.	-25.30	112.49	16.25	128.74
Employee Benefits Expenses	268.28	265.75	236.93	502.68
Financial Cost	143.61	159.72	109.85	269.57
Depreciation and Amortization Expenses	129.78	160.55	137.76	298.31
Other Expenses	478.62	367.7	390.41	758.11
TOTAL EXPENSES	6670.41	6062.24	6681.77	12744.01
Profit Before exceptional and extraordinary Items	628.29	600.97	559.60	1160.57
Exceptional Items	0	0	0	0.00
Profit Before Taxes	628.29	600.97	559.60	1160.57
Tax Expenses				
(a) Current Tax	162.30	165.42	144.45	309.87
(b) Deferred Tax (Liabilities)/Assets	2.56	-15.4	3.77	-11.63
(c) Prior Year Tax (Liabilities)/Assets	-0.71	0.36	15.08	15.44
Profit (Loss) for the period	464.14	450.59	396.30	846.89
Earning per equity share				
(a) Basic	2.98	3.10	2.85	5.82
(b) Dilluted	2.98	3.10	2.85	5.82

Notes For Standalone Financial Results :

- The above Standalone Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2025 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 13th November, 2025
- The above Standalone Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2025 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of The Companies (Indian Accounting Standards) Rules, 2015 as amended) and other recognised accounting practices and policies, as applicable.
- The Company operates only in one business segment viz " Intermediate Chemicals". Accordingly there are no seprate reporting segments as per Ind AS 108 " segment reporting".
- Previous year's/period's figure have been regrouped/rearranged/reclassified wherever necessary, to make them comparable with the figures of the current period.
- In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company

Place : Anand
Date : 13/11/2025

For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Managing Director
DIN No. : 00370715



STATEMENT OF STANDALONE ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2025

PARTICULAR	(Rs. In Lacs)	
	As At	As At
	30.09.2025	31.03.2025
	Unaudited	Audited
A. ASSETS		
1. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	1670.71	1706.56
(b) Intangible Assets	0.00	0.00
(c) Capital Work in Progress	421.73	84.73
(d) Intangible Assets under development	0	0.00
(e) Non Current Investments	1566.27	1566.27
(f) Deferred Tax assets(Net)	2.87	5.43
(g) Long term Loans and Advances	41.07	41.07
(h) Other Assets	161.96	379.62
Total Non Current Assets	3864.61	3783.68
2. CURRENT ASSETS		
(a) Inventories	4979.75	3518.03
(b) Financial Assets		
(i) Current Investments	0.00	0.00
(ii) Trade Receivable	4333.06	3441.48
(iii) Cash and Cash Equivalents	732.58	1048.16
(iv) Other Balance With Banks	536.43	2280.70
(v) Loans and Advances	840.86	840.26
(vi) Other Asstes	134.75	1700.56
Total Current Assets	11557.43	12829.19
TOTAL ASSETS	15422.04	16612.87
B. EQUITY AND LIABILITIES		
1. EQUITY		
(a) Equity Share Capital	1558.31	1558.31
(b) Other Equity	9476.95	9012.81
Total Equity	11,035.26	10571.12
2. LIABILITY		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	870.35	457.60
(b) Deferred Tax Liabilities	0.00	0.00
(c) Other Non Current Liabilities	0.00	0.00
Total Non Current Liabilities	870.35	457.60
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Trade Payables	1371.90	1079.36
(1) Total outstanding dues of MSME.	0.00	27.92
(2) Total outstanding dues Otherthan MSME.	1371.90	1051.44
(ii) Other Financial Liabilities	1879.06	4077.67
(b) Other Current Liabilities	17.32	2.96
(c) Provisions	75.42	114.29
(d) Income tax Liabilities	172.73	309.87
Total Current Liabilities	3516.43	5584.15
TOTAL	15422.04	16612.87

See Accompanying notes to the Financials results

For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Chairman
DIN No. : 00370715

Place : Anand
Date : 13/11/2025



STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2025		
Particular	(Rs. In Lacs)	
	As At 30.09.2025	As At 30.09.2024
	Unaudited	Unaudited
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before Tax	628.29	559.60
Adjustments for :		
Depreciation and Amortization	129.78	137.76
Financial Cost	143.61	109.85
Interest Received	(5.60)	(6.20)
Other Non Operating income	0.00	0.00
Operating Profit before working capital changes	896.08	801.01
Adjustments for (increase)/Decrease in operating assets :		
Trade Receivable	(891.58)	(132.15)
Inventories	(1461.72)	269.09
Loans and Advances	(0.60)	40.96
Other Current Assets	1565.81	(10.91)
Adjustments for increase/(Decrease) in operating liabilities :		
Trade Payable	292.54	399.32
Other Current Liabilities	14.36	6.84
Provisions	(176.01)	(245.96)
Cash Generated From Operations	238.88	1128.20
Direct Tax	(161.59)	(159.53)
Indirect Tax	0.00	0.00
Net Cash From Operating Activities (A)	77.29	968.67
B. Cash Flow from Investing Activities		
Purchase of Tangible Fixed Assets (Gross)	(430.93)	(260.16)
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00
Increase / (Decrease) in Non Current Assets	0.00	0.00
Long term Loans and Advances	0.00	(7.81)
Other Non Current Assets	217.66	(21.47)
Other Non Current Investments	0.00	(1532.16)
Interest Received	5.60	6.20
Other Non Operating income	0.00	0.00
Net Cash used in Investing Activities (B)	(207.67)	(1815.40)
C. Cash Flow from Financing Activities		
Proceeds from Issuing share	0.00	0.00
Share Premium Utilised in W/off IPO Expenses	0.00	0.00
Interest /Finacial Charges Paid	(143.61)	(109.85)
Non Current Laibilities	412.75	749.10
Other Financial Liabilities- Current	(2198.61)	594.86
Net Cash used in Financing Activities (c)	(1929.47)	1234.11
Net Increase / (Decrease) in cash and cash equivalents (A+B+C)	(2059.85)	387.38
Cash and cash equivalents at the beginning of the year	3328.86	817.65
Cash and cash equivalents at the end of the year	1269.01	1205.03
See Accompanying notes to the Financials results		

Place : Anand
Date : 13/11/2025

For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Chairman
DIN No. : 00370715



ASHOK RAJPARA & CO

Chartered Accountants

Independent Auditor's Review Report on Consolidated Unaudited Half Yearly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **INFINIUM PHARMACHEM LIMITED** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary constitute "the Group") for the half year ended September 30, 2025 ('the Statement'), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of interim Financial Information Performed by the Independent Auditor of the Entity's, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial Information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
 - i. Shanghai Tajilin Industrial Co Ltd. - China
 - ii. Infinium Green Energy Private Limited - India
 - iii. Infinium Healthcare Private Limited - India
5. The consolidated Unaudited Financial Results include the interim financial information of one subsidiary "Shanghai Tajilin Industrial Co Limited" which has not been reviewed by us and whose interim financial information reflects total revenue of Rs. 1992.75 Lacs, total net profit after tax of Rs. 126.32 Lacs for the half year ended September 30, 2025, which have been prepared by Independent CPA as per IFRS and approved by the Management.

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS
GUJARAT-395006

A/510, Diamond World, Nr. Mini Bazar, Varachha Road, Surat, Gujarat-395006
Ph. 9824745000 Email: carajpara@gmail.com

ASHOK RAJPARA & CO

Chartered Accountants

Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For , ASHOK RAJPARA & CO
CHARTERED ACCOUNTANTS


(ASHOK RAJPARA)
PROPRIETOR

M. No. 100559

FRN No : 153195W

UDIN : 25100559BMNYFB8037

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

Place : SURAT

Date : 13/11/2025

STATEMENT OF CONSOLIDATED FINANCIAL RESULT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2025

PARTICULARS	Half- year ended			(Rs. In Lacs)
	30.09.2025	31.03.2025	30.09.2024	Year ended
	Unaudited	Audited	Unaudited	31.03.2025 Audited
INCOME				
Revenue from Operations	8405.08	7272.81	8298.11	15570.92
Other Income, net	100.00	103.51	108.10	211.61
TOTAL INCOME	8505.08	7376.32	8406.21	15782.53
EXPENSES				
Cost of Matetrial Consumed	6364.63	5345.05	5583.82	10928.87
Purchases of Traded Goods	0.00	623.86	809.43	1433.29
Changes In Inventories of FG., WIP.	-11.53	-707.98	106.18	-601.80
Employee Benefits Expenses	399.27	370.65	372.28	742.93
Financial Cost	156.19	209.86	157.33	367.19
Deprecaition and Amortization Expenses	155.17	178.64	150.81	329.45
Other Expenses	608.31	846.35	579.25	1425.60
TOTAL EXPENSES	7672.05	6866.43	7759.10	14625.53
Profit Before Exceptional & Extraordinary Items	833.03	509.89	647.11	1157.00
Exceptional Items	0.00	0.00	0.00	0.00
Profit Before Taxes	833.03	509.89	647.11	1157.00
Tax Expenses				
(a) Current Tax	180.02	224.40	145.99	370.39
(b) Deffered Tax (Liabilities)/Assets	1.32	-16.10	2.87	-13.23
(c) Prior Year Tax (Liabilities)/Assets	-0.53	0.36	15.17	15.53
Profit after tax for the year	652.22	301.23	483.08	784.31
Less : Non Controlling Interest	92.16	-72.74	42.52	-30.22
Profit (Loss) for the period	560.06	373.97	440.56	814.53
Earing per equity share				
(a) Basic	3.59	2.57	3.17	5.60
(b) Dilluted	3.59	2.57	3.17	5.60

Notes For Consolidated Financial Results :

1. The above Consolidated Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2025 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 13th November, 2025

2. The above Consolidated Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2025 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of The Companies (Indian Accounting Standards) Rules, 2015 as amended) and other recognised accounting practices and policies, as applicable.

3. The following subsidiary company have been considered in the preparation of consolidated financial statements for the half year ended on 30th September, 2025

Name of the entity	Country Of Incorporation	% Of Holding
Shanghai Tajilin Industrial Co. Limited	China	51%
Infinium Green Energy Private Limited	India	51%
Infinium Healthcare Private Limited	India	51%

4. The Company operates only in one busines segment viz " Intermediate Chemicals".

5. Previous year's/period's figure have been regrouped/rearranged/reclassified wherever necessary, to make them comparable with the figures of the current period.

6. In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company

Place : Anand
Date : 13/11/2025



For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Managing Director
DIN No. : 00370715

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES FOR HALF YEAR ENDED ON 30th SEPTEMBER, 2025

PARTICULARS	(Rs. In Lacs)	
	For the half year ended on 30th September, 2025	For the year ended on 31st March, 2025
A. ASSETS		
I. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	2019.98	2076.20
(b) Intangible Assets	0.00	0.00
(c) Capital Work in Progress	471.44	84.72
(d) Intangible Assets : goodwill	339.45	339.45
(e) Non Current Investments	2902.48	2902.48
(f) Deferred Tax assets(Net)	14.61	14.89
(g) Long term Loans and Advances	46.59	46.59
(h) Other Assets	161.96	382.52
Total Non Current Assets	5956.51	5846.85
2. CURRENT ASSETS		
(a) Inventories	5997.88	4425.42
(b) Financial Assets		
(i) Current Investments	0.00	0.00
(ii) Trade Receivable	4505.68	3374.67
(iii) Cash and Cash Equivalents	1328.28	1150.13
(iv) Other Balance With Banks	160.23	2333.87
(v) Loans and Advances	778.48	807.00
(vi) Other Asstes	239.21	1900.60
Total Current Assets	13009.77	13991.69
TOTAL ASSETS	18966.27	19838.54
B. EQUITY AND LIABILITIES		
1. EQUITY		
(a) Equity Share Capital	1558.31	1558.31
(b) Other Equity	9922.90	9388.12
	11481.21	10946.43
(c) Non Controlling Interest	1625.48	1533.31
Total Equity	13106.69	12479.74
2. LIABILITY		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	1363.58	999.68
(b) Deferred Tax Liabilities	1.04	0.00
(c) Other Non Current Liabilities	10.66	0.00
Total Non Current Liabilities	1375.28	999.68
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Trade Payables	1768.08	1238.56
(ii) Other Financial Liabilities	1914.85	4184.94
(b) Other Current Liabilities	513.86	398.54
(c) Provisions	102.64	179.92
(d) Income tax Liabilities	184.88	357.16
Total Current Liabilities	4484.31	6359.12
TOTAL	18966.27	19838.54

See Accompanying notes to the Financials results

For, INFINIUM PHARMACHEM LTD

Place : Anand
Date : 13/11/2025

Sanjay V Patel
Chairman
DIN No. : 00370715



CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30th SEPTEMBER, 2025

Particular	(Rs. In Lacs)	
	For the half year ended on 30th September, 2025	For the half year ended on 30th September, 2024
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before Tax	833.03	647.11
Adjustments for :		
Depreciation and Amortization	155.17	150.81
Financial Cost	156.19	157.33
Interest Received	0.00	(6.39)
Other Adjustment non cash items -currency fluctuation reserve	(25.29)	0.00
Non Controlling Interest	(92.16)	(42.52)
Other Non Operating income		
Operating Profit before working capital changes	1026.94	906.34
Adjustments for (increase)/Decrease in operating assets :		
Trade Receivable	(1131.01)	(477.08)
Inventories	(1572.46)	393.65
Loans and Advances	28.52	(45.42)
Other Current Assets	1661.39	47.49
Adjustments for increase/(Decrease) in operating liabilities :		
Trade Payable	529.52	650.51
Other Current Liabilities	115.32	(128.28)
Provisions	(249.56)	(223.17)
Cash Generated From Operations	408.66	1,124.04
Direct Tax	(179.49)	(161.16)
Indirect Tax	0.00	0.00
Net Cash From Operating Activities (A)	229.17	962.88
B. Cash Flow from Investing Activities		
Purchase of Tangible Fixed Assets (Gross)	(485.67)	(1594.04)
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00
Increase / (Decrease) in Non Current Investment	0.00	(2902.49)
Non controlling Interest (BS)	92.17	1428.78
Long term Loans and Advances	0.00	(4.19)
Other Non Current Assets	220.56	(17.99)
Interest Received	0.00	6.39
Other Non Operating income	0.00	0.00
Net Cash used in Investing Activities (B)	(172.94)	(3083.54)
C. Cash Flow from Financing Activities		
Proceeds from Issuing share	0.00	0.00
IPO Expenses W/off	0.00	0.00
Interest /Financial Charges Paid	(156.19)	(157.33)
Non Current Liabilities	374.56	1692.82
Other Financial Liabilities- Current	(2270.09)	969.14
Net Cash used in Financing Activities (C)	(2051.72)	2,504.63
Net Increase / (Decrease) in cash and cash equivalents	(1995.49)	383.97
Cash and cash equivalents at the beginning of the year	3,484.00	1,191.21
Cash and cash equivalents at the end of the year	1,488.51	1,575.18

See Accompanying notes to the Financials results

Place : Anand
Date : 13/11/2025

For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Chairman
DIN No. : 00370715

